NeoMed Management is an international investment firm, exclusively focussing on the healthcare and life science industry. Founded in 1996, NeoMed has established four funds, with total committed capital exceeding $200 million.
|2017-09-18||Sonendo||Growth Equity||$50M||Fjord Ventures, General Atlantic, Henry Crown and Company, Meritech Capital Partners, and OrbiMed Advisors|
|2017-08-02||JenaValve Technology||Series E||$9.39M||Edmond de Rothschild Investment Partners, Gimv, and VI Partners|
|2017-06-21||Avitide||Series E||$12M||Borealis Ventures, Mithril Capital Management, OrbiMed Advisors, Polaris Partners, and Sands Capital|
|2017-05-02||Axonics Modulation Technologies||Series C||$14.5M||Advent Life Sciences, Cormorant Asset Management, Edmond de Rothschild Investment Partners, and Legend Capital|
|2017-04-26||Arsanis||Series D||$45.5M||Alexandria Venture Investments, Anna Maria and Stephen Kellen Foundation, Bill & Melinda Gates Foundation, EMBL Ventures, Google Ventures, OrbiMed Advisors, Polaris Partners, and SV Health Investors|